Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers fo ...
LUND, SE / ACCESS Newswire / February 19, 2025 /Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargia's management will participate in one-on-one ...
Savant Capital LLC lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 14.4% in the 4th ...
Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
NeuroPace expects to use approximately $49.5 million of the net proceeds from the offering to repurchase 5,270,845 shares of the Company’s common stock held by NeuroPace’s significant stockholder, KCK ...